tubulin beta 2B class IIbGenealiases: CDCBM7 · PMGYSA · bA506K6.1
Q-omics provides the consensus-scored TUBB2B profile across patient tissues and cancer cell-line models. TUBB2B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TUBB2B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TUBB2B protein abundance shows 17,452 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where TUBB2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBB2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBB2B survival associations across molecular data types. TUBB2B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBB2B RNA expression–survival associations across cancer types. High TUBB2B expression shows unfavorable associations in MESO, UCEC, ACC, THCA, STAD and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TUBB2B RNA expression.
This table summarizes TUBB2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TUBB2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBB2B shows lower tumor expression in KIRC, BRCA and COAD and higher tumor expression in LIHC, LUAD and LUSC. The KIRC box plot shows higher TUBB2B RNA expression in normal versus tumor tissue (log2 FC = −2.732, t-test p < 0.001).
This table shows molecular features associated with TUBB2B in patient tissues and cancer cell lines. In patient samples, TUBB2B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBB2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
